Silvia Jiménez-Jorge1, Francisco Pozo2, Amparo Larrauri3. 1. National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: silviajimenezjorge@gmail.com. 2. Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid, Spain. Electronic address: pacopozo@isciii.es. 3. National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: alarrauri@isciii.es.
Abstract
INTRODUCTION: The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain. METHODS: We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination. RESULTS: In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%). CONCLUSION: In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.
INTRODUCTION: The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain. METHODS: We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination. RESULTS: In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%). CONCLUSION: In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: George N Okoli; Florentin Racovitan; Christiaan H Righolt; Salaheddin M Mahmud Journal: Open Forum Infect Dis Date: 2020-05-21 Impact factor: 3.835
Authors: George N Okoli; Florentin Racovitan; Tiba Abdulwahid; Syed K Hyder; Louise Lansbury; Christiaan H Righolt; Salaheddin M Mahmud; Jonathan S Nguyen-Van-Tam Journal: Open Forum Infect Dis Date: 2021-02-05 Impact factor: 3.835
Authors: S G Sullivan; K S Carville; M Chilver; J E Fielding; K A Grant; H Kelly; A Levy; N P Stocks; S S Tempone; A K Regan Journal: Epidemiol Infect Date: 2016-04-29 Impact factor: 4.434
Authors: Benjamin J Cowling; Mike Y W Kwan; Joshua S C Wong; Shuo Feng; Chi-Wai Leung; Eunice L Y Chan; Kwok-Hung Chan; Tak-Keung Ng; Wing-Kin To; Malik J S Peiris; Susan S Chiu Journal: Influenza Other Respir Viruses Date: 2016-10-14 Impact factor: 4.380